Please login to the form below
tramiprosate
This page shows the latest tramiprosate news and features for those working in and with pharma, biotech and healthcare.
Spinraza keeps Biogen buoyant ahead of Alzheimer’s data
Earlier this week another drug in that category, Alzheon’s tramiprosate, also reported some encouraging data in a mid-stage trial, although that involved a subgroup of patients with a genetic
Latest news
-
Alzheon says data backs potential of Alzheimer's candidate
The cognitive effect increased significantly with time, suggesting a potential disease-modifying effect of tramiprosate," they conclude. ... Tramiprosate is thought to work by inhibiting the aggregation of beta amyloid monomers into toxic oligomers.
-
Signalling change
Another once-promising anti-amyloid drug, tramiprosate, was also abandoned by Bellus Health due to inconclusive phase III study findings.
-
Halted in its tracks
Tramiprosate is a B-amyloid inhibitor that is currently in phase III development with Neurochem. ... Data presented at ICAD 2006 showed tramiprosate halts B-amyloid-induced neuronal cell death in rats.
-
Dealing with dementia
A promising late-stage candidate is Neurochem's Alzhemed (tramiprosate). This drug works by mimicking and binding to glycosaminoglycan (GAG), which promotes the formation of the amyloid-beta plaques.
More from news
Approximately 1 fully matching, plus 4 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- AZ strengthens Daiichi Sankyo partnership with new ADC deal
- Gut instincts lead Takeda to GI pipeline success
- New study identifies drugs that are safe to use in COVID-19 treatment
- How will the events and exhibitions industry change post-Coronavirus?
- AbbVie exits Voyager alliance for Alzheimer’s/Parkinson’s gene therapies
- Eli Lilly begins COVID-19 prevention trial in nursing homes
- Porterhouse Medical Group joins imc group
- Biogen pays Denali $1bn upfront for Parkinson’s disease programme
- Tecentriq combo fails in advanced triple negative breast cancer
- Bristol-Myers Squibb’s revenues rise on Celgene acquisition
- Socially distanced strategising
- Artificial Intelligence in Digital Therapeutics
PMHub
IGNIFI
We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...
Latest intelligence
- Virtual Engagement At Porterhouse: Reflections on the past few months
- A look at how the pitfalls of virtual engagement can be avoided and the key advantages of virtual client and KOL engagement strategies in a now predominantly digital world....
- July 2020: diversity and inclusion in clinical trials round-up
- COVID-19 has continued to bring diversity and health inequality to the forefront of people’s attention. Our latest round-up covers the July news around these issues, and brings you the latest...
- Medical Device Clinical Trials 2020
- In July 2020, we attended and exhibited at the Medical Device Clinical Trials 2020 Virtual Experience. We really enjoyed the day and it was great to hear from like-minded people,...
Quick links
Infographics
